Fisher & Paykel Healthcare Corporation LimitedTeam Veye | 19 Mar 2020 ASX - FPH
Fisher & Paykel Healthcare Corporation Limited (ASX: FPH) designs, manufactures and markets medical device products and systems for use in respiratory care, acute care, surgery and the treatment of obstructive sleep apnea. The Company’s segment includes North America, which includes all activities controlled by entities or employees based in the United States and Canada; Europe, which includes all activities controlled by entities or employees based in the United Kingdom, France, Germany, Sweden, Turkey and Russia, and Asia-Pacific, which includes all activities controlled by entities or employees based in Australia, Japan, India, China, South Korea, Taiwan, and Hong Kong, and Other segment includes New Zealand, Latin America, Africa, the Middle East, and other countries. (Profile source: Reuters)
From the Company Reports
Fisher & Paykel Healthcare provides FY20 trading update
Fisher & Paykel Healthcare Corporation Limited on 17 March 2020 announced that it had further updated its revenue and earnings guidance for the financial year ended 31 March 2020.
(Chart source: TradingView)
The full-year guidance update provided in February, based on an NZ: US exchange rate of 64 cents, was for operating revenue to be approximately $1.2 billion and net profit after tax to be approximately $260 million to $270 million.
Since then, the NZ dollar has weakened against most currencies. Assuming an NZ:US exchange rate of approximately 61 cents and an NZ:EU exchange rate of approximately 55 cents for the rest of the financial year, the company expects full-year operating revenue to be approximately $1.24 billion and net profit after tax to be within the range of approximately $275 million to $280 million.
Fisher & Paykel Healthcare updates revenue and earnings guidance on stronger Hospital and Homecare sales
Fisher & Paykel Healthcare Corporation Limited on 21 February 2020 announced that it had updated its revenue and earnings guidance for the financial year ended 31 March 2020.
The full-year guidance previously provided in November, based on an NZ: US exchange rate of 64 cents, was for operating revenue to be approximately $1.19 billion and net profit after tax to be approximately $255 million to $265 million.
Mr. Lewis Gradon, Managing Director and CEO said the company has received inquiries about possible impacts to the company’s supply chain resulting from coronavirus. Fisher & Paykel Healthcare does not have a manufacturing facility in China; however, some of its suppliers of raw materials are based in China.
Fisher & Paykel Healthcare launches new Evora™ compact nasal mask for sleep apnea
Fisher & Paykel Healthcare Corporation Limited on 3 February 2020 announced the launch of F&P Evora™, a new nasal mask for the treatment of obstructive sleep apnea (OSA).
(Graphic Source – Company Reports)
F&P Evora is a compact nasal mask that sits comfortably under the nose. The mask features CapFit™ headgear, which is designed to be put on like a baseball cap in one simple and intuitive movement. In a clinical trial*, 98 percent of participants described Evora as “simple to take off and put on in the dark,” and 95 percent of respiratory therapists found the mask “simple to fit.”
Evora also features a ‘floating’ seal, which sits inside stability wings. These technologies work together to allow for freedom of movement during sleep while keeping the mask comfortably in place.
Evora offers OSA patients the performance benefits of a nasal mask, with the streamlined design and minimalism of a nasal pillow mask, said Lewis Gradon, Managing Director and CEO of Fisher & Paykel Healthcare. Its unique and innovative features make fitting the mask much easier for the patient and the respiratory therapist.
Strong Half Year Result for Fisher & Paykel Healthcare: Net Profit Up 24%
Fisher & Paykel Healthcare Corporation Limited on 27 November 2019 announced its financial results for the half-year ended 30 September 2019. Net profit after tax was $121.2 million, up 24%, and operating revenue was $570.9 million, 12% above the first half last year
(Graphic Source – Company Reports)
In the Hospital product group, which includes humidification products used in respiratory, acute and surgical care, operating revenue increased 19% to a record of $353.6 million. This represented 17% growth in constant currency, during an extended flu season in the United States. Products in the Hospital group made up 62% of the company’s operating revenue.
In the Homecare product group, which includes products used in the treatment of obstructive sleep apnea (OSA) and respiratory support in the home, operating revenue rose 2% to NZ$214.7 million, or a decline of 1% in constant currency.
Gross margin increased by 26 basis points to 67.1% compared to the first half last year, with benefits from product mix offsetting the additional start-up costs of the company’s second Mexico manufacturing facility.
(Graphic Source – Company Reports)
Overview of key results for the first half
- 24% growth in net profit after tax to a record of $121.2 million.
- 23% increase in interim dividend to 12 cps (2019: 9.75 cps).
- 12% growth in operating revenue to a record $570.9 million, 9% growth in constant currency.
- 19% growth in Hospital operating revenue, 17% growth in constant currency.
- 23% constant currency revenue growth for new applications consumables; i.e. products used in non-invasive ventilation, Optiflow nasal high flow therapy, and surgical applications, accounting for 63% of Hospital consumables revenue.
- 2% growth in Homecare operating revenue, 1% decline in constant currency.
- 1% decline in constant currency revenue in OSA masks. Investment in R&D was 9% of revenue, or $54 million.
|Daily average Volume (10 Days)||20.683M|
|Yearly Dividend Yield||0.94%|
|Target Price (s)||$32.50|
|52 weeks High||27.96|
|52 weeks Low||14.00|
|Directors||Lewis Gradon, Managing Director & Chief|
|Non-executive Directors||Michael Daniell
Fisher & Paykel Healthcare’s half-year Net profit after tax was $121.2 million, up 24%, and operating revenue was $570.9 million, 12% above the first half last year. It had a strong start to the 2020 financial year, mainly driven by the Hospital product group, which delivered an operating revenue growth of 19 percent. FPH’s respiratory humidifiers and consumables are directly involved in treating patients with coronavirus. The company has seen an increase in demand globally and thus ramped up its manufacturing output. At the same time, FPH benefited from stronger sales in its Homecare product group and a weakening of the NZ dollar. There were better-than-expected sales in its Homecare product group combined with continued strong growth in the Hospital product group. This includes an increase in demand from China related to the COVID-19 coronavirus outbreak. The stock has been moving in an uptrend for four months now. After the fall last week, the stock soon reversed and has formed an inverse head & shoulder pattern. The stock can have good growth potential as the company continues to innovate to improve care and develop new applications for its technologies. Veye recommends a "Buy" on “Fisher & Paykel Healthcare Corporation Limited” at the current price of $27.00
Veye Pty Ltd (ABN 58 623 120 865) authorised representative (AR No. 001261006) of Vested Equities Pty Ltd which holds an Australian Financial Services License (AFSL No. 478987). Veye is authorised to share only generic financial views through its website, reports and newsletters without taking into consideration your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure the accuracy of the content and that the information is gathered and processed from reliable resources, it is recommended you seek professional advice from your financial advisor or stockbroker before acting on any of our recommendations. Veye Pty Ltd advises it’s users to pursue investing as a long-term goal. Stocks are subject to real time changes therefore all the information we share represents our views at the date of publishing and we request our readers not to interpret our reports as direct recommendations. Past performance is no indication of potential future performance. The securities and financial products we study and share information on in Veye Reports may have a product disclosure statement or other offer document associated with them. You should obtain a copy of these documents before making any decision about acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Veye Pty Ltd confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report (as mentioned on the website www.veye.com.au).